This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Educational Activities

Switching Therapies in MS: What Are the Options?

Article Abstract

Relapses or suboptimal response in multiple sclerosis (MS), also known as breakthrough disease, is common, even in patients with good adherence to disease-modifying medications. To confirm breakthrough disease, clinicians must assess adherence, ensuring to manage any adverse effects that could lead to nonadherence; monitor disease course through clinical and MRI measures; and then make treatment adjustments as appropriate. For patients with suboptimal response, clinicians may change the dosage or switch or combine disease-modifying treatments. Switching from first-line treatments (interferon use β or glatiramer acetate) to second-line treatments (natalizumab or mitoxantrone) or to an oral medication (fingolimod, teriflunomide, dimethyl fumarate) requires knowledge of the risks and benefits associated with each agent. Clinicians who recognize breakthrough disease can intervene to reduce disability in their patients with MS.

From the Department of Neurology and the Multiple Sclerosis Center, the Hospital of the University of Pennsylvania, Philadelphia.

This CME activity is expired. For more CME activities, visit cme.psychiatrist.com.
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

Related Articles

Volume: 76

Quick Links: Multiple Sclerosis , Neurologic and Neurocognitive

References